Study wrapper · #943
Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review.
Takrori E, Peshin S, Singal S Medicina (Kaunas, Lithuania). 2025.
DOI: 10.3390/medicina61111987PubMed: 41303824
Editor's note
This review synthesizes twelve studies on gastrointestinal tolerability of anti-obesity drugs in non-diabetic adults, finding nausea, vomiting, diarrhea, and constipation most common with GLP-1 agonists during dose escalation. Symptoms were generally mild to moderate but can affect adherence. The authors note heterogeneity in study design as a limitation.
Plain-language abstract
A systematic review of twelve studies found that gastrointestinal side effects such as nausea, vomiting, and diarrhea are common with anti-obesity medications, particularly GLP-1 receptor agonists.
Related coverage
Mixed
Hunger pain and its reduction; qualitative insight from people with schizophrenia on semaglutide.
International journal of qualitative studies on health and well-beingn=——2026
Weak / none
Design, synthesis, and stability evaluation of semaglutide-derived lactam-stapled peptide scaffolds for GLP-1R targeting.
Journal of enzyme inhibition and medicinal chemistryn=——2026
Mixed
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
Journal of obstetrics and gynaecologyn=——2026